Takeda Pharmaceuticals U.S.A., Inc. or TPUSA (TKPYY.PK) and Affymax, Inc. (AFFY) Monday said Takeda Pharmaceuticals America, Inc. or TPA has entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the U.S. Financial terms were not disclosed.
Omontys is the only once-monthly erythropoiesis-stimulating agent for anemia available to the adult dialysis patient population with chronic kidney disease in the U.S.
The agreement allows DSI Renal to purchase Omontys for use within its organization and provides for discounts and rebates on the product. DSI Renal has indicated that it plans to initially evaluate Omontys in selected centers, and then, based on experience, evaluate the potential to expand to additional centers.
Omontys was approved by the U.S. Food and Drug Administration on March 27, 2012, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
For comments and feedback: editorial@rttnews.com